Aldoclor-250 en es it fr

Aldoclor-250 Brand names, Aldoclor-250 Analogs

Aldoclor-250 Brand Names Mixture

  • No information avaliable

Aldoclor-250 Chemical_Formula


Aldoclor-250 RX_link

Aldoclor-250 fda sheet

Aldoclor-250 FDA

Aldoclor-250 msds (material safety sheet)

Aldoclor-250 MSDS

Aldoclor-250 Synthesis Reference

No information avaliable

Aldoclor-250 Molecular Weight

1270.28 g/mol

Aldoclor-250 Melting Point

No information avaliable

Aldoclor-250 H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Aldoclor-250 State


Aldoclor-250 LogP

No information avaliable

Aldoclor-250 Dosage Forms

Powder for solution (for injection)

Aldoclor-250 Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Aldoclor-250 Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Aldoclor-250 Absorption

No information avaliable

Aldoclor-250 side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Aldoclor-250 Patient Information

No information avaliable

Aldoclor-250 Organisms Affected

Aspergillis, Candida and other fungi